MEMacy L. Early

Macy L. Early

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Macy L. Early has a total of 39 co-authors. Here are the top co-authors by number of shared publications:

  • Lydia H. Pecker

    Division of General Internal Medicine, Department of Medicine Johns Hopkins University School of Medicine Baltimore Maryland USA

    4 shared publications
  • Sophie Lanzkron

    Division of Hematology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland

    4 shared publications
  • Lydia H. Pecker

    Division of Hematology, Johns Hopkins University School of Medicine, Baltimore, MD

    3 shared publications
  • Ahizechukwu C. Eke

    Division of Maternal-Fetal Medicine, Department of Gynecology and Obstetrics, Johns Hopkins University School of Medicine, Baltimore, Maryland

    2 shared publications
  • Alison Gemmill

    Department of Population, Family and Reproductive Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland

    2 shared publications
  • Ann Kinga Malinowski

    Department of Obstetrics and Gynecology, Department of Health Research Methods Evidence and Impact McMaster University Hamilton Ontario Canada

    2 shared publications

Latest Publications

  • Risk factors for antepartum venous thromboembolism in pregnant people with sickle cell disease

    by Gloria F. Gerber, Sacha Choupa, Amy Luo, Vinal Menon, Nadine Shehata, Jayla Scott, Macy L. E. Gatti, Michael B. Streiff, Rakhi P. Naik, Kevin Kuo, et al.

    Summary: Sickle cell disease (SCD) is a thrombophilia exacerbated by pregnancy. However, there is not strong evidence for thromboprophylaxis, perhaps because most data addressing pregnancy‐related thrombosis in SCD is limited by derivation from administrative datasets. We studied venous thromboembolism (VTE) in a retrospective cohort of pregnant people with SCD who delivered singleton pregnancies at two academic centres between 1990 and 2021. Among 289 pregnancies to 197 SCD subjects, 6% had VTE. We compared characteristics of the first study pregnancy in which a VTE occurred (cases) to the first study pregnancy in subjects without pregnancy‐related VTE (controls). Preconception complications associated with VTE were history of VTE (cases: 33% [ n = 5/15] vs. controls: 4% [ n = 7/182], p < 0.001), acute chest syndrome (ACS) (80% [ n = 12/15] vs. 37% [ n = 68/182], p = 0.001) and acute care for vaso‐occlusive crisis (VOC) in the year before pregnancy (80% [ n = 12/15] vs. 43% [ n = 70/182], p = 0.006). Prenatal complications associated with VTE were ACS (47% [ n = 7/15] vs. 10% [ n = 19/182], p < 0.001) and VOC (93% [ n = 14/15] vs. 65% [ n = 119/182], p = 0.026). Fetal outcomes associated with VTE included gestational age at delivery (median [IQR] 37.0 [34.0–38.1] weeks vs. 38.3 [36.9–39.3], p = 0.004). Studies are needed to establish interventions that attenuate VTE risk and define prophylactic anti‐coagulation parameters for this high‐risk population.

  • No difference in alloimmunization of pregnant adults with sickle cell disease exposed to chronic versus on‐demand transfusions: A two‐center retrospective cohort study

    by Clare Zarka, David Daniel, Vinal Menon, Sacha Choupa, Macy L. E. Gatti, Amy Luo, Kevin Kuo, A. Kinga Malinowski, Sophie Lanzkron, Nadine Shehata, et al.

    Background: Pregnant people with sickle cell disease (SCD) experience high morbidity and mortality, even when RBC transfusion is safe and available. There is a lack of consensus on transfusion use partly due to concern for alloimmunization. This study examined alloimmunization in SCD pregnancies managed with chronic transfusion therapy (CTT) versus on‐demand transfusion (ODT). A secondary aim was to quantify the proportion of SCD pregnancies that met guideline indications for CTT that received CTT in pregnancy. Study Design: This is a two‐center, retrospective study of pregnancy in SCD over two decades. We compared alloimmunization between those who received CTT versus ODT by examining the Sickle Cell Pregnancy and Reproductive Knowledge Syndicate database. A secondary analysis applied American Society of Hematology (2020) and/or British Society for Haematology (2021) criteria for CTT in pregnancy to calculate guideline compliance. Results: Among 145 subjects, 26 received CTT and 119 received ODT. Alloimmunization incidence was 4%, with no significant difference by transfusion group (1/26 CTT vs. 5/119 ODT, p = 1.0). Five ODT subjects became alloimmunized (5/46). One CTT subject was alloimmunized (1/26) after receiving an unplanned ODT. Of all pregnancies, 87% met ASH criteria and 65% met BSH criteria for CTT, while 20% received CTT. Discussion: For patients with SCD in pregnancy, CTT may not pose a greater alloimmunization risk than ODT. CTT may be underutilized for SCD in pregnancy. Our study is limited by incomplete data and variable antigen matching practices. Prospective research will help establish the appropriate role of CTT in SCD pregnancies.

  • Top Cited Papers

    Severe Maternal Morbidity and Mortality in Sickle Cell Disease in the National Inpatient Sample, 2012-2018

    by Macy L. Early, Ahizechukwu C. Eke, Alison Gemmill, Sophie Lanzkron, Lydia H. Pecker

    Importance: Pregnancy outcomes are historically poor among people with sickle cell disease (SCD) in the US, most of whom have Black race. Whether outcomes have improved is unknown.Objective: To tabulate adverse pregnancy outcomes among patients with SCD, comparing outcomes of deliveries among Black people with SCD with those of Black people without SCD and a control non-Black population, and to measure the association of racial disparities with adverse outcomes in SCD pregnancies.Design, Setting, and Participants: This cross-sectional study was a secondary analysis involving data from National Inpatient Sample, a nationally representative sample of 20% of acute hospital admissions in the US, between 2012 and 2018. The data set included all admissions with codes for delivery of a pregnancy among people aged 11 to 55 years. Data were analyzed from September 2021 to August 2022.Exposures: SCD, racial disparities.Main Outcomes and Measures: Severe maternal morbidity (SMM) as measured by the US Centers for Disease Control and Prevention’s index alongside other outcomes; multiple logistic regression was used to compare the odds for adverse pregnancy outcomes.Results: The sample included 5 401 899 deliveries, including 3901 deliveries among people with SCD and 742 164 deliveries among people with Black race. Compared with the non-Black control group, patients with SCD and Black patients were younger (mean [SD] age: SCD, 27.2 [5.9] years; Black, 27.1 [6.1] years vs 28.7 [5.9] years) and more likely to have public insurance (SCD, 2609 deliveries [67.3%]; Black, 496 828 deliveries [65.4%] vs 1 880 198 deliveries [40.8%]). The maternal mortality rate in deliveries among people with SCD was 26 times greater than in the non-Black control group and more than 10 times greater than among Black pregnant people without SCD (Per 10 000 deliveries: SCD 13.3; 95% CI, 5.7-31.2; Black race, 1.2; 95% CI, 1.0-1.5; non-Black control 0.5; 95% CI, 0.5-0.6). Compared with the control group, SCD deliveries had higher odds of SMM (adjusted odds ratio [aOR], 7.22; 95% CI, 6.25-8.34; P < .001), especially cerebrovascular events (aOR, 22.00; 95% CI, 15.25-31.72; P < .001) and thromboembolism (aOR, 17.34; 95% CI, 11.55-26.03; P < .001). Racial disparities explained a median (IQR) 28.9% (21.2%-33.1%) of the increased risk in deliveries to people with SCD and between 40% and 50% of the increased risk for acute kidney failure (excess risk [ER], 56.9%; 95% CI, 54.3%-59.3%), intrauterine fetal demise (ER, 47.8%; 95% CI, 46.6%-49.1%), and eclampsia (ER, 42.1%; 95% CI, 37.9%-46.1%).Conclusions and Relevance: In this large cross-sectional study of pregnancy outcomes in people with SCD, the risk for SMM was higher compared with deliveries among people without SCD, especially for thrombotic events, organ failure, and death. Racial disparities were associated with adverse outcomes. Our findings compel scientific, clinical, and political effort to improve outcomes for pregnant people with SCD.


  • Comparisons of Severe Maternal Morbidity and Other Adverse Pregnancy Outcomes in Pregnant People With Sickle Cell Disease vs Anemia

    by Macy L. Early, Ahizechukwu C. Eke, Alison Gemmill, Sophie Lanzkron, Lydia H. Pecker

    Pregnancy in people with sickle cell disease (SCD) is high risk. There are 50 years of data finding several-fold increased rates of severe pregnancy complications and maternal mortality in pregnancies among individuals with SCD.1-3 The pathophysiology of SCD is complex and characterized by inflammation, endothelial dysfunction, vaso-occlusion, and anemia.4 Anemia may be a mediator associated with some portion of the risk for severe maternal morbidity (SMM) and other adverse pregnancy outcomes (APOs) in pregnancy among individuals with SCD (eFigure in Supplement 1).


  • Open Access

    The Montreal cognitive assessment as a cognitive screening tool in sickle cell disease: Associations with clinically significant cognitive domains

    by Macy L. Early, Elizabeth Linton, Allison Bosch, Timothy Campbell, Felicia Hill‐Briggs, Lydia H. Pecker, Eboni I. Lance, Sophie Lanzkron

    Summary: Adults with sickle cell disease (SCD) are at risk for cognitive impairment, which causes significant morbidity. Guidelines support routine cognitive screening, but no screening test is validated in this population. We explored the Montreal Cognitive Assessment (MoCA) as a possible screening test in SCD. We administered the MoCA; a literacy test, the Wide Range Achievement Test, fourth edition (WRAT‐4); and a health literacy test, the Shortened Test of Functional Health Literacy in Adults (S‐TOFHLA) to adults with SCD and gathered clinical variables through chart review. Spearman's rho, Mann–Whitney, and Kruskal–Wallis tests and quantile regression models were used. Among our sample of 49 adults with SCD, the median MoCA score was 25.0 [interquartile range (IQR) 22.0–28.0]. Higher educational attainment was associated with MoCA scores (p = 0.001). In multivariable models, MoCA scores were associated with S‐TOFHLA (p = 0.001) and WRAT‐4 Reading (p = 0.002) scores, and overt stroke (p = 0.03) at the median. This pilot study adds to the limited literature of cognitive screening tests in adults with SCD and demonstrates a relationship between MoCA scores and measures of literacy and health literacy. The MoCA is a promising option for briefly screening for cognitive impairment in adults with SCD, though further study is needed to confirm its validity.


  • Acceptable, hopeful, and useful: development and mixed-method evaluation of an educational tool about reproductive options for people with sickle cell disease or trait

    by Macy L. Early, Rachel J. Strodel, Isabel V. Lake, Jake A. Ruddy, James A. Saba, Sajya M. Singh, Sophie Lanzkron, Jennifer W. Mack, Emily R. Meier, Mindy S. Christianson, et al.

    Purpose People with sickle cell disease (SCD) or trait have many reproductive options, some of which decrease the chance of passing SCD to children, including in vitro fertilization with preimplantation genetic testing (IVF + PGT). Few are aware of these options, and educational materials are needed. This study aimed to develop an accessible, non-directive patient education material about reproductive options for those with SCD or trait via a process that incorporated stakeholders from the SCD community. Methods Multidisciplinary stakeholders guided development and revision of a novel pamphlet. Researchers applied health literacy scales to measure pamphlet understandability. We interviewed nine patients with SCD and six multidisciplinary clinicians to evaluate the pamphlet. Interviews were recorded, transcribed, and coded by a five-member team who developed a codebook and proposed themes that were revised by all research team members. Feedback was incorporated into a revised pamphlet. Results A two-page pamphlet describing reproductive options for people with SCD including IVF + PGT was acceptable to key stakeholders, including people with SCD. Material about this complex topic met health literacy standards, including being written at a 5th grade level. Patients reported feeling hopeful after reviewing the pamphlet, and participants considered the pamphlet useful, clear, and appropriate for distribution in clinics and online. Conclusions Though awareness of reproductive options for those with SCD or trait is low, patients and providers find a novel pamphlet about this topic acceptable and useful. Educational materials about complex topics including IVF + PGT can be written at a level understandable to the average American.


  • Literacy assessment of preimplantation genetic patient education materials exceed national reading levels

    by Macy L. Early, Priyanka Kumar, Arik V. Marcell, Cathleen Lawson, Mindy Christianson, Lydia H. Pecker

    Purpose In vitro fertilization with preimplantation genetic testing (IVF+PGT-M) reduces the risk of having a child affected by a heritable condition, yet only one-third of eligible patients are aware of this reproductive option. Access to education materials written at appropriate literacy levels could raise patients’ awareness, but there is a mismatch between patient reading ability and the literacy demand of most materials. This study aimed to systematically identify written education materials on IVF+PGT-M and evaluate their literacy levels. We hypothesized that materials would fail to meet standards set by the Joint Commission and Centers for Disease Control and Prevention (CDC). Methods To identify patient education materials about IVF+PGT-M from academic databases and public-facing sources, an environmental scan was performed. Materials were analyzed using three validated scales: Simple Measure of Gobbledygook, Patient Education Materials Assessment Tool, and Clear Communication Index. Results Seventeen patient education materials about IVF+PGT-M were identified from patient education databases, a consumer search engine, and professional organizations. The median reading level was 14.5 grade, median understandability was 74.2%, and median comprehensibility was 73.3%. Conclusions For most American adults, materials about IVF+PGT-M are not readable, understandable, or clear. The Joint Commission requires patient education materials be written at or below 5th grade reading level and the CDC recommends a 90% minimum score for comprehensibility. No evaluated material met these guidelines. Patient education materials that exceed average American literacy skills may perpetuate disparities in the utilization of IVF+PGT-M. Materials that communicate this complicated subject at an understandable level are needed.